• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    千

    千里金兰大学

    senri kinran üniversitesi
    院校
    136论文总数
    1,496引用总数

    论文量&引用量时间轴

    机构学者

    论文(136)

    年份
    起
    –
    止
    排序
    1P2.427: Survey of ISODP 2025 Attendees on Donor Family Support Following Deceased Organ Donation.
    Miho Shingu, Akemi Hirao, Naomi Ueyama, Keiko Yasuoka,Norihide Fukushima
    2026Transplantation(2026)
    引用
    AI阅读
    加入学术空间
    2Nationwide Evolution of Durable Left Ventricular Assist Device Outcomes Following Introduction of the HeartMate 3 and Destination Therapy in Japan -the Third Official Report from J-MACS -
    Teruhiko Imamura,Koichiro Kinugawa,Takashi Nishimura,Koichi Toda,Yoshikatsu Saiki,Hiroshi Niinami,Shinichi Nunoda,Goro Matsumiya,Hirokuni Arai,Masanobu Yanase,Norihide Fukushima,Takeshi Nakatani,

    Background: The nationwide impact in Japan of contemporary improvement in the clinical management of durable left ventricular assist device (LVAD), together with the introduction of the HeartMate 3 (Abbott, Pleasanton, CA, USA), on clinical outcomes remains uncertain. Methods and Results: Using the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS), we analyzed all patients undergoing durable LVAD implantation in Japan between 2011 and 2025. Patients were divided into an early era (up to 2018) and the contemporary era (since 2019), reflecting introduction of the HeartMate 3 in Japan. The primary outcome was all-cause mortality during LVAD support. Among 1,859 patients, 1,587 underwent bridge-to-transplantation and 272 underwent destination therapy. Survival improved significantly in the contemporary era compared with the early era (5-year survival 84% vs. 76%, respectively; P=0.0002). Device dysfunction-free, pump thrombus-free, stroke-free, major bleeding-free, and pump exchange-free survival also improved significantly after 2019 (all P<0.0001). Right ventricular failure and ventricular arrhythmia that required appropriate defibrillation remained frequent complications. Among patients who received a durable LVAD since 2019, destination therapy recipients had lower survival than bridge-to-transplantation recipients (3-year survival 81% vs. 91%; P=0.0057). Conclusions: Clinical outcomes after durable LVAD implantation improved substantially following the introduction of HeartMate 3 in Japan, particularly regarding pump-related and hemocompatibility-related complications. However, right ventricular failure and ventricular arrhythmia remain major unresolved challenges.

    2026CIRCULATION JOURNAL(2026)
    引用
    AI阅读
    加入学术空间
    3P1.068: Survey of ISODP 2025 Attendees on Family Support in Pediatric Organ Donation after Brain Death.
    Natsuko Ishii, Naomi Ueyama, Miho Shingu, Mikiko Nakada,Norihide Fukushima
    2026Transplantation(2026)
    引用
    AI阅读
    加入学术空间
    4Reduced Adverse Events Without Survival Benefit with HeartMate 3 Vs. HeartMate II in Japan
    Teruhiko Imamura,Masahiko Ando,Koichiro Kinugawa,Takashi Nishimura,Koichi Toda,Yoshikatsu Saiki,Hiroshi Niinami,Shinichi Nunoda,Goro Matsumiya,Hirokuni Arai,Masanobu Yanase,Norihide Fukushima,

    Background: HeartMate 3 (Abbott Laboratories), a fully magnetically levitated left ventricular assist device (LVAD), has shown improved hemocompatibility vs. previous devices, but nationwide real-world data in Japan remain limited. Methods and Results: Using the Japanese nationwide registry for Mechanically Assisted Circulatory Support (J-MACS), we analyzed patients who underwent de novo implantation of HeartMate 3 or HeartMate II between 2013 and 2025. The primary outcome was a composite of all-cause death, stroke, and device dysfunction requiring exchange or explantation within 2 years. In all, 978 patients were included in the study (HeartMate 3, n=486; HeartMate II, n=492). The 2-year cumulative incidence of the primary outcome was significantly lower in the HeartMate 3 group than in the HeartMate II group (9% vs. 23%; P<0.001). HeartMate 3 was independently associated with a lower risk of the primary outcome (adjusted hazard ratio 0.35; 95% confidence interval 0.23-0.51; P<0.001), which remained consistent in competing-risk and several statistically matched analyses. The incidence of hemocompatibilityrelated adverse events, including major bleeding, stroke, and device dysfunction, was significantly lower in the HeartMate 3 group. In contrast, 2-and 5-year overall mortality did not differ significantly between groups (<10% for both devices). Conclusions: In this nationwide Japanese registry, HeartMate 3 reduced major LVAD-related complications without improving survival, supporting its clinical advantages in contemporary LVAD management.

    2026CIRCULATION JOURNAL(2026)
    引用
    AI阅读
    加入学术空间
    5
    茜 田野, 瑶 肖, 好美 奥村
    2026Studies on Educational Methodology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 136 篇论文

    合作机构(100)

    大阪大学合作论文 23
    岩手大学合作论文 12
    东北大学(日本)合作论文 9
    京都大学合作论文 7
    九州大学合作论文 6
    Tokyo Metropolitan Industrial Technology Research Institute合作论文 6
    麻布大学合作论文 6
    大阪市立大学合作论文 5
    东京大学合作论文 5
    文教大学合作论文 5

    机构统计